The device aims to provide a less invasive alternative to traditional blood-based testing.
The diagnostic kit measures glycated albumin, a key biomarker for diabetes, using semiconductor biosensor technology that integrates next-generation surface technology with antibody conjugation techniques.
DYD’s platform has already received technology certification from the Ministry of Trade, Industry and Energy in South Korea. Additionally, the company has completed reproducibility verification through clinical trials conducted at Maryland Medical Center in the United States.
The saliva-based testing method offers significant advantages over conventional blood-based diagnostics.
“We aim to provide a more convenient and accurate monitoring environment for diabetes patients worldwide through our entry into the global diagnostic kit market,” a DYD spokesperson said.
Copyright ⓒ Aju Press All rights reserved.
View more comments